Tetrate and Federal Agency NIST Cohost ZTA and DevSecOps Conference 2022 Kicking Off With Istio and Envoy Training
5.1.2022 16:07:00 EET | Business Wire | Press release
Tetrate, the leading company providing a zero-trust application connectivity platform, announced their third annual conference on Zero Trust Architecture (ZTA) and DevSecOps for Cloud Native Applications in partnership with the U.S. National Institute of Standards and Technology (NIST), the federal organization responsible for creating security standards. The NIST–Tetrate multi-cloud conference is a premier event for CISOs, platform architects, and tech leadership from federal and corporate organizations.
The virtual conference will take place on January 27 from 8:00 a.m. – 5:00 p.m. EST and will be preceded by a 2.5-hour training on January 26, showcasing the implementation of Zero Trust Architecture on an actual Platform One deployment. This year’s conference will focus on DevSecOps and ZTA as foundational approaches to developing, deploying, and operating high assurance, cloud native applications. Featured speakers include: André Mendes, Department of Commerce CIO; Kelsey Hightower, Principal Engineer Google Cloud; Ronald Ross, NIST Fellow; and Zack Butcher, Tetrate Founding Engineer. The conference has seen tremendous growth in attendance over the past three years. Past speakers have included Nicolas Chalain, the U.S. Air Force’s first Chief Software Officer, and Zulfikar Ramzan, CTO of RSA Security.
“Cybersecurity incidents are one of the biggest issues facing organizations today, especially as the world moves towards cloud-native applications,” said David Ferraiolo of NIST. “Developing, deploying, and operating zero-trust enabled applications to achieve security, reliability, and resiliency is extremely important for organizations to feel secure.”
“Over the last three years, the NIST–Tetrate conference has featured dialogues and workshops from the world’s most esteemed service mesh and cybersecurity experts," said Varun Talwar, co-founder of Tetrate. "The growth in popularity of the conference is a testament to the importance of ZTA and DevSecOps in a multi-cloud environment. This year, again, we're thrilled to gather together and offer our global community valuable insights and perspectives from top visionaries."
Cloud-native applications often consist of microservices deployed across a combination of public cloud, private cloud, and on-prem, also known as heterogeneous infrastructure. This has created challenges related to connectivity, security, and reliability for delivering high-assurance applications, leading to the popularity of DevSecOps and ZTA. Service mesh plays a critical role in incorporating zero-trust design and DevSecOps principles by adding security and reliability to connect microservices across infrastructures without any additional code.
The conference will feature presentations by domain experts, practitioners, and thought leaders in DevSecOps and Zero Trust Architecture (ZTA) deployments, as well as demonstrations of proof-of-concept use cases in multi-cloud environments. Presentations will address the following:
- ZTA guiding principles and approaches for workflow, system design, and operations through DevSecOps pipelines, authentication and authorization frameworks, and continuous monitoring;
- NIST’s latest guidance on DevSecOps and security engineering practices;
- The role of automation in operational security;
- The benefits of prescribed approaches, such as prevention of configuration drift and continuous authority to operate.
In addition to a lineup of notable speakers, the training on January 26 will help deliver an educational experience where attendees will learn new skills and cover the deployment of a zero-trust platform with the use of Istio, Kubernetes, and other tools to implement the following security components:
- in-app and user-level security permissions,
- encryption in transit,
- enhanced identity and access controls, and
- runtime observability.
Tetrate also provides free passes, on request, to application security professionals who need the $35 fee waived.
Join the virtual event: Registration page
- Join and follow the conversation with hashtag #ZTACon2022 #DevSecOps
- Twitter: @tetrateio
- LinkedIn: Tetrate
- YouTube: Tetrate
For more information regarding ZTA and DevSecOps Conference 2022, an entirely virtual experience taking place this week, please visit: https://www.tetrate.io/zta-devsecops-conference-2022.
About Tetrate–NIST Collaboration
Tetrate and NIST have collaborated over the last three years across multiple deliverables. Using NIST’s experience with cybersecurity and Tetrate’s expertise on secure service mesh, they have collaborated to produce U.S. security standards for a distributed architecture:
- (SP 800-204A) Building Secure Microservices-based Applications Using Service-Mesh Architecture,
- (SP 800-204B) Attribute-based Access Control for Microservices-based Applications using a Service Mesh,
- (SP 800-204C) Implementation of DevSecOps for a Microservices-based Application with Service Mesh, and
- Implementation of Next Generation Access Control (NGAC), a superior authorization framework that’s more fine-grained than role-based access control (RBAC) and attribute-based access control (ABAC), in Tetrate’s products.
About Tetrate
Started by Istio founders to reimagine application networking, Tetrate is an enterprise service mesh company managing the complexity of modern, hybrid cloud application infrastructure. Customers get consistent, baked-in observability, runtime security, and traffic management in any environment. Its flagship product, Tetrate Service Bridge, provides an edge-to-workload application connectivity platform to deliver business continuity, agility, and security for enterprises on the journey from traditional monoliths to the cloud. Tetrate remains a top contributor to the open-source projects Istio and Envoy Proxy. Find out more at www.tetrate.io.
About NIST
The National Institute of Standards and Technology (NIST) was founded by the U.S. Congress in 1901 and is now part of the U.S. Department of Commerce. NIST is one of the nation's oldest physical science laboratories. From the smart electric power grid and electronic health records to atomic clocks, advanced nanomaterials, and computer chips, innumerable products and services today rely in some way on technology, measurement, and standards provided by NIST.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005433/en/
Contact information
Annie Fink, Bospar
Annie@bospar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
